These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23606532)

  • 1. Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells.
    Chen HY; Yang YM; Stevens BM; Noble M
    EMBO Mol Med; 2013 May; 5(5):723-36. PubMed ID: 23606532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Redox biology in normal cells and cancer: restoring function of the redox/Fyn/c-Cbl pathway in cancer cells offers new approaches to cancer treatment.
    Noble M; Mayer-Pröschel M; Li Z; Dong T; Cui W; Pröschel C; Ambeskovic I; Dietrich J; Han R; Yang YM; Folts C; Stripay J; Chen HY; Stevens BM
    Free Radic Biol Med; 2015 Feb; 79():300-23. PubMed ID: 25481740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cool-1-mediated inhibition of c-Cbl modulates multiple critical properties of glioblastomas, including the ability to generate tumors in vivo.
    Stevens BM; Folts CJ; Cui W; Bardin AL; Walter K; Carson-Walter E; Vescovi A; Noble M
    Stem Cells; 2014 May; 32(5):1124-35. PubMed ID: 24458840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42.
    Hirsch DS; Shen Y; Wu WJ
    Cancer Res; 2006 Apr; 66(7):3523-30. PubMed ID: 16585176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemically diverse toxicants converge on Fyn and c-Cbl to disrupt precursor cell function.
    Li Z; Dong T; Pröschel C; Noble M
    PLoS Biol; 2007 Feb; 5(2):e35. PubMed ID: 17298174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells.
    Li W; Xu L; Che X; Li H; Zhang Y; Song N; Wen T; Hou K; Yang Y; Zhou L; Xin X; Xu L; Zeng X; Shi S; Liu Y; Qu X; Teng Y
    BMC Cancer; 2018 May; 18(1):507. PubMed ID: 29720121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ubiquitin ligase c-Cbl is involved in tamoxifen-induced apoptosis of MCF-7 cells by downregulating the survival signals.
    Yan SC; Liu YP; Zhang LY; Qu JL; Xu L; Liu J; Zhang Y; Hou KZ; Teng YE; Qu XJ
    Acta Oncol; 2011 Jun; 50(5):693-9. PubMed ID: 21175263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the estrogen receptor-positive breast cancer genome: not even the end of the beginning.
    Van Tine BA; Ellis MJ
    J Natl Cancer Inst; 2011 Apr; 103(7):526-7. PubMed ID: 21447809
    [No Abstract]   [Full Text] [Related]  

  • 9. CBL enhances breast tumor formation by inhibiting tumor suppressive activity of TGF-β signaling.
    Kang JM; Park S; Kim SJ; Hong HY; Jeong J; Kim HS; Kim SJ
    Oncogene; 2012 Dec; 31(50):5123-31. PubMed ID: 22310290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cbl escapes Cdc42-mediated inhibition by downregulation of the adaptor molecule betaPix.
    Schmidt MHH; Husnjak K; Szymkiewicz I; Haglund K; Dikic I
    Oncogene; 2006 May; 25(21):3071-8. PubMed ID: 16407834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.
    Fernandes MS; Reddy MM; Croteau NJ; Walz C; Weisbach H; Podar K; Band H; Carroll M; Reiter A; Larson RA; Salgia R; Griffin JD; Sattler M
    J Biol Chem; 2010 Oct; 285(42):32596-605. PubMed ID: 20622007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b.
    Vennin C; Spruyt N; Dahmani F; Julien S; Bertucci F; Finetti P; Chassat T; Bourette RP; Le Bourhis X; Adriaenssens E
    Oncotarget; 2015 Oct; 6(30):29209-23. PubMed ID: 26353930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-216a rescues dexamethasone suppression of osteogenesis, promotes osteoblast differentiation and enhances bone formation, by regulating c-Cbl-mediated PI3K/AKT pathway.
    Li H; Li T; Fan J; Li T; Fan L; Wang S; Weng X; Han Q; Zhao RC
    Cell Death Differ; 2015 Dec; 22(12):1935-45. PubMed ID: 26206089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1.
    Zhu Y; Liu Y; Zhang C; Chu J; Wu Y; Li Y; Liu J; Li Q; Li S; Shi Q; Jin L; Zhao J; Yin D; Efroni S; Su F; Yao H; Song E; Liu Q
    Nat Commun; 2018 Apr; 9(1):1595. PubMed ID: 29686231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation.
    Wu WJ; Tu S; Cerione RA
    Cell; 2003 Sep; 114(6):715-25. PubMed ID: 14505571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
    Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
    Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR.
    Thomas C; Rajapaksa G; Nikolos F; Hao R; Katchy A; McCollum CW; Bondesson M; Quinlan P; Thompson A; Krishnamurthy S; Esteva FJ; Gustafsson JÅ
    Breast Cancer Res; 2012 Nov; 14(6):R148. PubMed ID: 23158001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E3 Ubiquitin Ligase Cbl-b Prevents Tumor Metastasis by Maintaining the Epithelial Phenotype in Multiple Drug-Resistant Gastric and Breast Cancer Cells.
    Xu L; Zhang Y; Qu X; Che X; Guo T; Cai Y; Li A; Li D; Li C; Wen T; Fan Y; Hou K; Ma Y; Hu X; Liu Y
    Neoplasia; 2017 Apr; 19(4):374-382. PubMed ID: 28334634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein.
    Salazar MD; Ratnam M; Patki M; Kisovic I; Trumbly R; Iman M; Ratnam M
    Breast Cancer Res; 2011 Feb; 13(1):R18. PubMed ID: 21299862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
    Wen J; Li R; Lu Y; Shupnik MA
    Oncogene; 2009 Jan; 28(4):575-86. PubMed ID: 18997820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.